Breast Cancer

Testing for HER2 overexpression in breast cancer can affect treatment decisions.

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence.

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence.

Adding Avastin to standard therapy delays progression of advanced HER2-negative breast cancer in women without prior treatment.

A large phase III study examining whether the addition of Tarceva (erlotinib) to Avastin (bevacizumab) delayed progression of advanced non-small cell lung cancer reached its primary goal.

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence.

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed.

A new class of drugs called PARP inhibitors is getting some serious attention in metastatic triple-negative breast cancers.

For 25 years, surgical and medical oncologists have gathered in sunny Miami to discuss the latest strategies in breast cancer management.

The 8th Annual Conference for Young Women Affected by Breast Cancer welcomed women diagnosed with breast cancer at 40 or younger.

Is it best to start with tamoxifen and then switch to an aromatase inhibitor (AI), or should the AI come first?

Gene testing now recommended before colon cancer treatment

An unexpected survivor addresses breast cancer risk

Treatment updates from the 2009 ASCO Gastrointestinal Cancers Symposium.

Breast cancer survivors find healing in the challenges of the road.

A brief from this year's San Antonio Breast Cancer Symposium discussing what new agents researchers have been testing when treating HER2-positive breast cancer.

A discussion about the best schedule for a class of drugs continues at the San Antonio Breast Cancer Symposium.

CURE Editor-at-Large, Kathy LaTour, tells the story of metastatic cancer survivor Brenda Hutchinson and her involvment with the HER2 Support Group

A brief from this year's San Antonio Breast Cancer Symposium where research was presented on the benefits that the drug Doxil can provide women who have relapsed after anthracycline treatment.

A brief from this year's San Antonio Breast Cancer Symposium discusses new research from eight clinical trials that studied whether or not certain factors help to predict response to neoadjuvant therapy prior to surgery.

A brief from this year's San Antonio Breast Cancer Symposium discussing new data showing that patients who receive radiation after having a mastectomy have a lesser chance of recurrence in certain early-stage cancers.

Advocate Joan Venticinque blogs about patient advocacy.

CURE publisher Susan McClure blogs from a survivor's perspective.

How a better understanding of cancer metastasis is suggesting better treatment approaches.

Why one family is committed to educating the public about male breast cancer.

A brief from this year's San Antonio Breast Cancer Symposium discussing IBIS-1, a trial that examines tamoxifen's effectiveness as a breast cancer prevention drug, and how breast density is effected by Tamoxifen.

A brief summarizing significant news from this year's San Antonio Breast Cancer Symposium regarding the TransATAC study's results showing that Oncotype DX may now be available for use in women who have taken aromatase inhibitors.

A brief from this year's San Antonio Breast Cancer Symposium detailing research from the AZURE trial that indicates adding the drug Zometa to chemotherapy before surgery may help to shrink breast tumors by an additional third.

Advocate Joan Venticinque blogs about patient advocacy.